Table 1 ESCAT proposal for glioma tumors according to the most recent evidence
ESCAT | Alteration | Matched therapy and ESMO MCBS | Patients with alteration | Patients tested | Prevalence | Altered patients by ESCAT | Total by group |
|---|---|---|---|---|---|---|---|
Tier 1 | BRAF - V600E mutation | Dabra-Trame: 3 | 7 | 497 | 1,4% | 144 | 168 |
IDH1 mutation | Vorasidenib: 3 | 123 | 535 | 23,0% | 31,1% | ||
IDH2 mutation | Vorasidenib: 3 | 10 | 492 | 2,0% | |||
NTRK (1-3) fusion | Larotrecitnib/ Entrectinib: ND | 10 | 489 | 2,0% | |||
Tier 2 | FGFR (1-3) pathogenic mutations | Erdafitinib: 3 | 14 | 482 | 2,9% | 24 | |
FGFR rearrangement (FGFR-TACC) | Futibatinib/ Pemigatinib: 3 | 13 | 473 | 2,7% | |||
Tier 3 | AKT1 - E17K mutation | - | 0 | 467 | 0,0% | 153 | 303 |
BRAF fusionsa | Selumitinib: ND | 8 | 495 | 1,6% | 56,0% | ||
FGFR (1-3) amplification | Erda/Futi/Pemi: ND | 3 | 459 | 0,7% | |||
H3K27M mutation | - | 11 | 455 | 2,4% | |||
MET mutation | Vebreltinib/ Capmatinib: ND | 10 | 469 | 2,1% | |||
PI3K mutations (PIK3CA, PTEN) | Capmatinib: ND | 149 | 492 | 30,3% | |||
PTEN loss | - | 19 | 479 | 4,0% | |||
Tier 4 | ATM mutation | - | 14 | 349 | 4,0% | 150 | |
ATRX mutation | ATR inhibitor: ND | 80 | 459 | 17,4% | |||
CDKN2A loss | - | 127 | 445 | 28,5% | |||
CDKN2B loss | - | 108 | 393 | 27,5% | |||
EGFR amplification | Depatuxizumab mafodotin/Dacomitinib: ND | 128 | 482 | 26,6% | |||
EGFR mutation | - | 69 | 497 | 13,9% | |||
EGFR vIII rearrangement | EGFRvIII-TCBA/Rindopepimut: ND | 72 | 492 | 14,6% | |||
pTERT mutation | - | 205 | 437 | 46,9% | |||
Wild type | 40 | 541 | 7,4% | ||||
Unknown | Incomplete results | 30 | 541 | 5,5% | |||
Total | 541 |
